$0.59 EPS Expected for Supernus Pharmaceuticals, Inc. (SUPN)

Investors sentiment decreased to 0.94 in Q2 2019. Its down 0.77, from 1.71 in 2019Q1. It dropped, as 28 investors sold Supernus Pharmaceuticals, Inc. shares while 83 reduced holdings. 32 funds opened positions while 72 raised stakes. 48.47 million shares or 20.16% less from 60.70 million shares in 2019Q1 were reported.
Acadian Asset Lc holds 0.09% or 588,401 shares in its portfolio. Icon Advisers Co invested 0.24% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). South Dakota Inv Council accumulated 76,500 shares or 0.05% of the stock. Mutual Of America Cap Management Limited Co reported 384,017 shares or 0.18% of all its holdings. Voloridge Investment Mngmt Ltd holds 0.03% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for 33,516 shares. Manufacturers Life Insur Com The holds 31,034 shares or 0% of its portfolio. Macquarie Group Incorporated Ltd invested in 1.08M shares or 0.06% of the stock. The Georgia-based Signaturefd Limited Liability Corp has invested 0% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Strs Ohio accumulated 90,000 shares or 0.01% of the stock. 27,326 are owned by Thb Asset. Alps Advsr holds 0% or 10,004 shares in its portfolio. Moreover, Chatham Group Inc has 0.16% invested in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Arizona State Retirement Systems holds 0.03% or 81,259 shares in its portfolio. Amalgamated Financial Bank owns 9,356 shares. Panagora Asset accumulated 366,003 shares.

Since August 23, 2019, it had 1 buy, and 0 sales for $189,982 activity.

Analysts expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report $0.59 EPS on November, 5.They anticipate $0.07 EPS change or 13.46 % from last quarter’s $0.52 EPS. SUPN’s profit would be $30.33M giving it 11.41 P/E if the $0.59 EPS is correct. After having $0.61 EPS previously, Supernus Pharmaceuticals, Inc.’s analysts see -3.28 % EPS growth. The stock decreased 0.97% or $0.26 during the last trading session, reaching $26.92. About 884,237 shares traded or 68.04% up from the average. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has declined 36.98% since October 7, 2018 and is downtrending. It has underperformed by 36.98% the S&P500.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $1.38 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 13.87 P/E ratio. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

More notable recent Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news were published by: Globenewswire.com which released: “Supernus Hosts Conference Call to Present Topline Results of Final Phase III Study for SPN-812 in Adolescents with ADHD – GlobeNewswire” on March 27, 2019, also Seekingalpha.com with their article: “Revisiting Supernus Pharmaceuticals – Seeking Alpha” published on September 27, 2018, Globenewswire.com published: “Supernus Announces Positive Results from Two Phase III Studies For SPN-812 in Children with ADHD – GlobeNewswire” on December 06, 2018. More interesting news about Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) were released by: Globenewswire.com and their article: “Supernus to Acquire Biscayne Neurotherapeutics Nasdaq:SUPN – GlobeNewswire” published on September 13, 2018 as well as Globenewswire.com‘s news article titled: “Supernus Announces P304 Phase III Data Confirming Positive Results from Previous Three Phase III Studies on SPN-812 in ADHD – GlobeNewswire” with publication date: March 28, 2019.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.